PPARA and diabetic kidney disease: Studies have reported that AdipoRon may be a promising agent to treat diabetic nephropathy by stimulating intracellular calcium ions, activating the AMPK-LKB1/PPARα signaling pathway, and increasing ceramidase activity via activation of AdipoRs and downstream targets [32].